A Phase 2a, Randomized, Open-Label, Active Control, Multi-Center Study to Assess the Efficacy and Safety of Bleselumab in Preventing the Recurrence of Focal Segmental Glomerulosclerosis in de Novo Kidney Transplant Recipients
Phase of Trial: Phase II
Latest Information Update: 27 Sep 2017
At a glance
- Drugs Bleselumab (Primary) ; Basiliximab; Meprednisone; Meprednisone; Mycophenolate mofetil; Mycophenolate mofetil; Prednisone; Tacrolimus; Tacrolimus
- Indications Focal segmental glomerulosclerosis
- Focus Therapeutic Use
- Sponsors Astellas Pharma
- 28 Jun 2017 Planned End Date changed from 30 Mar 2020 to 1 May 2020.
- 28 Jun 2017 Planned primary completion date changed from 4 Sep 2019 to 1 Sep 2019.
- 31 May 2017 Planned End Date changed from 1 Mar 2019 to 30 Mar 2020.